Blood:定量蛋白质组学揭示AML干细胞的独特代谢特征

2020-06-22 医刀 MedSci原创

高分辨率蛋白质组学可明确与健康的HSPC相比经过功能验证的LSC中活跃的特征性通路和可靶向通路;代谢途径的改变主要表现在蛋白质上,在转录本水平上并不明显,这突出了蛋白质组学分析的优势。

急性髓性白血病(AML)的特征是无法分化为成熟白细胞的克隆性髓母细胞细胞的积累。化疗可以使大多数患者缓解,但是复发率很高,并导致临床预后不良。这主要是由对化疗耐药的白血病干细胞(LSC)引起的,因此必须根除LSC以提高患者生存率。

既往主要在转录水平上研究LSC,因此缺乏有关转录后调控基因和相关网络的信息。Raffel等人将既往关于LSC蛋白质组的报告扩展到健康的年龄匹配的造血干细胞和祖细胞(HSPC),并将蛋白质组与相应的转录组相关联。

通过将LSC与白血病母细胞和健康的HSPC进行比较,Raffel等人验证了LSC的候选标记物,并突出显示了在HSPC中不存在或很少表达的新型、潜在可靶向的蛋白质。

此外,该研究数据还提供了有力的证据,表明LSC具有独特的能量代谢、粘附分子组成以及RNA加工特性。将相同个体的样品的蛋白质组和转录数据关联起来也突出了蛋白质组分析的重要性,这在检测代谢通路的改变方面特别有效。

总而言之,该研究为功能验证的LSC、母细胞和健康的HSPC提供了全面的蛋白质组学和转录组学表征,有助于开发LSC导向的疗法。

原始出处:

Simon Raffel,et al. Quantitative proteomics reveals specific metabolic features of Acute Myeloid Leukemia stem cells. Blood. June 18,2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754855, encodeId=15a51e5485548, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Thu Jan 21 00:34:26 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025470, encodeId=c1ce10254e02a, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jun 25 16:34:26 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297114, encodeId=f635129e11420, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 24 07:34:26 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765830, encodeId=0e011e658308c, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 24 08:34:26 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1754855, encodeId=15a51e5485548, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Thu Jan 21 00:34:26 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025470, encodeId=c1ce10254e02a, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jun 25 16:34:26 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297114, encodeId=f635129e11420, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 24 07:34:26 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765830, encodeId=0e011e658308c, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 24 08:34:26 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
    2020-06-25 独孤立克

    干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1754855, encodeId=15a51e5485548, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Thu Jan 21 00:34:26 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025470, encodeId=c1ce10254e02a, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jun 25 16:34:26 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297114, encodeId=f635129e11420, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 24 07:34:26 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765830, encodeId=0e011e658308c, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 24 08:34:26 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1754855, encodeId=15a51e5485548, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Thu Jan 21 00:34:26 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025470, encodeId=c1ce10254e02a, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Thu Jun 25 16:34:26 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297114, encodeId=f635129e11420, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jun 24 07:34:26 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765830, encodeId=0e011e658308c, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 24 08:34:26 CST 2021, time=2021-04-24, status=1, ipAttribution=)]

相关资讯

Astellas宣布其FLT3抑制剂XOSPATA治疗白血病,正在NMPA接受监管审查

Gilteritinib属于第二代FLT3抑制剂,可抑制FLT3跨膜区内部串联重复(ITD)以及FLT3酪氨酸激酶结构域(TKD),这是2种常见的FLT3突变类型,约占所有AML病例的三分之一。

NCCN临床实践指南:急性髓性白血病(2020.V2)

2019年9月,美国国家综合癌症网络(NCCN)发布了急性髓性白血病指南2020年第2版,指南主要内容包括: 指南更新摘要 急性白血病和诊断研究评估(AML-1) APL,诱导治疗(AML-2) APL,诱导治疗和巩固治疗(AML-3) APL,巩固后治疗(AML-6) APL,复发治疗(AML-7) AML,标准剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-8) AML,大剂量阿糖胞苷诱导

CC-486治疗急性髓性白血病:FDA授予优先审查权

百时美施贵宝(Bristol Myers Squibb)近日表示,FDA授予了CC-486治疗成人急性髓性白血病(AML)的优先审查权。

Cell Death Dis:离子通道TRPM2通过调节线粒体功能、ROS及自噬促进AML细胞增殖

研究发现在AML中TRPM2具有高表达水平。本研究通过CRISPR/Cas9技术在U937细胞中敲除TRPM2来研究其在AML中的作用。

放线菌素D纳米粒子治疗急性髓性白血病

Tiziana是一家专注于炎症、自身免疫和传染病创新疗法的生物技术公司,近日宣布,根据一项资产购买协议,该公司已收购了Rasna制药公司的放线菌素D(Act D)纳米颗粒制剂的全部知识产权。

NCCN临床实践指南:急性髓性白血病(2020.V1)

2019年8月,美国国家综合癌症网络(NCCN)发布了急性髓性白血病指南2020年第1版,指南主要内容包括: 指南更新摘要 急性白血病和诊断研究评估(AML-1) APL,诱导治疗(AML-2) APL,诱导治疗和巩固治疗(AML-3) APL,巩固后治疗(AML-6) APL,复发治疗(AML-7) AML,标准剂量阿糖胞苷诱导缓解后治疗(年龄<60y)(AML-8) AML,大剂量阿糖胞苷诱导